Menu
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Forum
No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700
www.novocure.com
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and nine months ended September 30, 2023, at 8 a.m. EDT on Thursday, October 26, 2023. To access the conference
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about methods to optimize TTFields intensities delivered at the target
Its cancer-treating device is struggling to find its market.
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in
The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price. Healthcare companies can see a massive surge in their share price, following encouraging treatment outcomes, but the reverse is also true. If results are lackluster, the stock price could plummet. It is a double-edged sword, and investors can get burned quickly if they’re not careful about investing in the biotech and pharmaceutical industry. Let’s look at three healthcare companies that investors should avoid at this time. Sage Therapeutics (SAGE) Source: Andrus Ciprian / Shutterstock.com Sage Therapeutics (NASDAQ: SAGE ) is a biopharmaceutical company that develops medicines to treat neurologic disorders of the brain. Their flagship medication Zulresso is an injection to treat postpartum depression, and their only novel therapy publicly marketed now.
It''s entering a risky period, but it could persevere.
Novocure announced a disappointing outcome from a phase 3 clinical trial for a key cancer treatment.
It can be hard to find a reason to remain bullish on NovoCure.
ROOT, Switzerland---- Novocure announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of
